)
Product Pipeline
Focused on Innovation
CSL Behring is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma fractionation, recombinant technology, and cell and gene therapy to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in five Therapeutic Areas - Immunology, Hematology, Cardiovascular and Metabolic, Respiratory and Transplant. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.
Core Capabilities
Phase 1
Phase 2
Phase 3
Registration / Post-Registration
CSL324 Anti-G-CSFR mAb (HS)
Recombinant monoclonal antibody against the cytokine granulocyte colony stimulating factor receptor for the potential treatment of Hidradenitis Suppurativa (HS).
CSL730 Recombinant Trivalent Human IgG1 Fc Multimer*
Novel recombinant trivalent human IgG1 Fc multimer for treatment of patients with immune complex-mediated autoimmune diseases such Myasthenia Gravis (MG) and Lupus Nephritis (LN).
*Developed in collaboration with Momenta Pharmaceuticals.
CSL889 Hemopexin (SCD)
Plasma-derived Hemopexin for the potential treatment of Sickle Cell Disease (SCD).
CSL787 Nebulized Ig (NCFB)
Human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non-Cystic Fibrosis Bronchiectasis (NCFB).
CSL311 Anti-Beta Common mAb (Asthma)
Fully human monoclonal antibody inhibiting GM-CSF, IL-3 and IL-5 signalling by neutralizing the ß-common receptor for the potential treatment of complex inflammatory diseases such as asthma.
ASLAN004 Anti-IL-13R mAb (AD)
Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis (AD) and asthma.
Licensed to ASLAN Pharmaceuticals.
HIZENTRA® (SSc)
20% subcutaneous immunoglobulin, for the treatment of Systemic Sclerosis (SSc).
Garadacimab Anti-FXIIa mAb (ILD/IPF)
A humanised anti-FXIIa monoclonal antibody for the potential treatment of Interstitial Lung Diseases (ILD) and Idiopathic Pulmonary Fibrosis (IPF).
CSL346 Anti-VEGFB mAb (DKD)
Humanised monoclonal antibody targeting VEGF-B for the potential treatment of diabetic kidney disease (DKD).
Mavrilimumab Anti-GM-CSFR mAb (GCA, COVID-19)*
Recombinant monoclonal antibody against the granulocyte macrophage colony-stimulating factor receptor as a potential treatment for inflammatory diseases.
*Licensed to Kiniksa Pharmaceuticals.
Garadacimab Anti-FXIIa mAb (HAE)
Humanised anti-factor XIIa monoclonal antibody for the potential treatment of Hereditary Angioedema (HAE) by subcutaneous administration.
HIZENTRA® (DM)
20% subcutaneous immunoglobulin for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).
EtranaDez Etranacogene dezaparvovec (Hem B)
Recombinant adeno-associated viral vector of serotype 5 (AAV5) gene therapy containing the Padua variant of a codon-optimized human FIX complementary deoxyribonucleic acid (AAV5-Padua hFIX) for the treatment of Hemophilia B.
KCENTRA® 4F-PCC (Trauma)
A 4-factor prothrombin complex concentrate (4F-PCC) for the potential treatment of massive hemorrhage associated with severe traumatic injury.
CSL112 ApoA-I (AMI)
Novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with myocardial infarction (AMI).
Clazakizumab Anti-IL-6 mAb (AMR)
Humanized recombinant monoclonal antibody targeting interleukin-6 (IL-6) for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients.
CSL964 Alpha-1 Antitrypsin (Prevention of GvHD)
Prevention of acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
CSL964 Alpha-1 Antitrypsin (Treatment of GvHD)*
Treatment of steroid refractory, acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
*In collaboration with Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
HAEGARDA® (HAE)
Self-administered, subcutaneous C1-esterase inhibitor (human) for routine prophylaxis to prevent HAE attacks.
HIZENTRA® (SCIg) 20% Liquid
20% subcutaneous immunoglobulin.
PRIVIGEN® (IVIg) 10% Liquid
10% intravenous immunoglobulin.
AFSTYLA® rFVIII (Hem A)
Novel, recombinant factor VIII product for the treatment of adults and children with hemophilia A.
IDELVION® rFIX-FP (Hem B)
Novel, long-acting recombinant factor IX product for the treatment of hemophilia B.
ZEMAIRA®/RESPREEZA® Alpha-1 Proteinase Inhibitor (AAT Deficiency)
Alpha-1 Proteinase Inhibitor (Human) for treatment of Alpha-1 Antitrypsin (AAT) Deficiency.